Measures relating to use of drug subsidy lists and to regulation

International Journal of Risk and Safety in Medicine

Volumn 15, Issue 1-2, 2002, Pages 77-79

  Mitchell, A S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUSTRALIA; COMPARATIVE STUDY; COST UTILITY ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; REVIEW;

EID: 0036968405     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Anon, Dutch finalising pharmaco-economic guidelines, SCRIP 6 (23-25 December 1998), 2398-2399.
2. Canadian Coordinating Office for Health Technology Assessment, Guidelines for Economic Evaluation of Pharmaceuticals: Canada, 2nd edn, CCOHTA, Ottawa, 1997.
3. Commonwealth of Australia, Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses, Department of Health and Aged Care, Canberra, 1995. Available from http://www.health.gov.au/pbs/pubs/pharmpac/gusubpac.htm.
4. M.F. Drummond, B. O'Brien, G.L. Stoddardt and G.W. Torrance, Methods for the Economic Evaluation of Health Care Programmes, 2nd edn, Oxford University Press, Oxford, 1997.
5. S. Hill, D. Henry, B. Pekarsky and A. Mitchell, Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence? The Australian experience, Br. J. Clin. Pharmacol. 44 (1997), 421-425.
6. S. Hill, A.S. Mitchell and D.A. Henry, Problems with the interpretation of pharmacoeconomic analyses: A review of submissions to the Australian pharmaceutical benefits scheme, JAMA 283 (2000), 2116-2121.
7. A. Laupacis, D. Feeny, A.S. Detsky and P.X. Tugwell, Tentative guidelines for using clinical and economic evaluations revisited, Can. Med. Assoc. J. 148 (1993), 92-99.
8. A. Mitchell, Update and Evaluation of Australian guidelines: Government perspective, Med. Care 34 (1996), DS216-DS225.
9. Ontario Ministry of Health, Ontario Guidelines for Economic Analysis of Pharmaceutical Products, Ministry of Health, Toronto, 1994.
10. République Française, Acceptabilité des Etudes Médico-économiques: Contenu et Présentation. Saint-Denis: Agence du Médicament, 1995.